CURI
CuriosityStream Inc.
CURI's fundamentals are strong: its operating margin went from −12% to 10% and revenue grew 18%, though free cash flow fell 55%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NBIS
Nebius Group N.V.
There isn't enough reported data to score NBIS yet.
CURI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CURI's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NBIS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Healthy |
NBIS's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
CURI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $2.86 | — |
| Current | 20x | $2.86 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
CURI has the edge over NBIS in the historical PE scenario, which offers more potential upside but is not a forecast.
NBIS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 68x | $22.45 | -83% |
| Fair | 114x | $37.67 | -71% |
| Current | 390x | $129 | — |
| Expensive | 666x | $220 | +71% |
Historical ranges are pointers, not guarantees.
NBIS's PE is 390x, but its earnings don't support one, so it isn't a reliable read right now.
CURI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CURI has the edge over NBIS on the outlook, with more favorable earnings expectations.
NBIS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NBIS's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
CURI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.24 | +75% |
| Q3 2026 | $0.14 | +$0.23 |
| Q2 2026 | $0.00 | +$0.09 |
| Q1 2026 | -$0.14 | $0.00 |
| Q4 2025 | -$0.11 | +$0.13 |
| Q3 2025 | -$0.09 | +$0.18 |
| Q2 2025 | -$0.09 | +$0.62 |
| Q1 2025 | -$0.14 | +$0.72 |
| Q4 2024 | -$0.24 | +$0.68 |
CURI has the edge over NBIS in the latest year-over-year earnings comparison.
NBIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.33 | +$2.61 |
| Q4 2024 | -$2.28 | -456% |
| Q4 2023 | $0.64 | -36% |
| Q4 2022 | $1.00 | +$1.49 |
| Q4 2021 | -$0.49 | -156% |
| Q4 2020 | $0.87 | +89% |
| Q4 2019 | $0.46 | -73% |
| Q4 2018 | $1.71 | +434% |
NBIS has returned to profit: it earned $0.33 per share over the past year, after losing money the year before.
CURI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +13% |
| Q2 2026 | $23.2M | +22% |
| Q1 2026 | $15.2M | +0.5% |
| Q4 2025 | $19.2M | +36% |
| Q3 2025 | $18.4M | +46% |
| Q2 2025 | $19M | +53% |
| Q1 2025 | $15.1M | +26% |
| Q4 2024 | $14.1M | -4.3% |
CURI has the edge over NBIS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +42 points |
| Q2 2026 | 39% | +37 points |
| Q1 2026 | -10% | -11 points |
| Q4 2025 | -18% | +9.9 points |
| Q3 2025 | -24% | +1.3 points |
| Q2 2025 | 2.5% | +23 points |
| Q1 2025 | 0.5% | +31 points |
| Q4 2024 | -27% | +4.8 points |
CURI's operating margin was 18% last quarter, up 42 points from the same quarter a year ago, near the top of its range since 2019.
NBIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $9.7B | +53% |
| Q4 2022 | $6.3B | +46% |
| Q4 2021 | $4.3B | +63% |
| Q4 2020 | $2.6B | +24% |
| Q4 2019 | $2.1B | +37% |
| Q4 2018 | $1.5B | +36% |
| Q4 2017 | $1.1B | +24% |
| Q4 2016 | $917M | +27% |
NBIS's revenue is growing: $530M last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -115% | -112 points |
| Q4 2023 | 3.6% | -11 points |
| Q4 2022 | 2.5% | -14 points |
| Q4 2021 | -3.7% | -18 points |
| Q4 2020 | 7.4% | -9.5 points |
| Q4 2019 | 14% | -2 points |
| Q4 2018 | 16% | -14 points |
| Q4 2017 | 14% | -19 points |
NBIS's operating margin was −115% last quarter, down 123 points from the same quarter a year ago, near the bottom of its range since 2011.
CURI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | +0.5% |
| Q2 2026 | -$4.2M | -249% |
| Q1 2026 | $1.2M | -34% |
| Q4 2025 | $3.9M | +30% |
| Q3 2025 | $4.4M | +94% |
| Q2 2025 | $2.8M | +27% |
| Q1 2025 | $1.8M | +177% |
| Q4 2024 | $3M | +$5.6M |
CURI has burned cash in most quarters: $5M over the past year, down 55% from the year before.
NBIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.7B | -$3.1B |
| Q4 2024 | -$562.1M | -$316.2M |
| Q4 2023 | -$245.9M | -$138.9M |
| Q4 2022 | -$107M | +$319.7M |
| Q4 2021 | -$426.7M | -539% |
| Q4 2020 | $97.3M | -66% |
| Q4 2019 | $287.9M | +$289.2M |
| Q4 2018 | -$1.3M | -101% |
NBIS has burned cash in six of the last eight quarters: −$4.6B over the past year, against −$43M the year before.
CURI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -164K shares |
| 1 year | +4.3% | +2.5M shares |
| 3 years | +14% | +7.4M shares |
| 5 years | +26% | +12.4M shares |
| Available history | +264% | +43.9M shares |
CURI has 60M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $560,000 |
| Q1 2026 | $311,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $33,000 |
| Q3 2024 | $192,000 |
| Q4 2020 | — |
CURI spent $871,000 buying back its own shares over the past year.
NBIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -33.3M shares |
| 1 year | -32% | -115M shares |
| 3 years | -26% | -86.9M shares |
NBIS has the edge over CURI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | $10M |
| Q4 2021 | $84.1M |
| Q4 2020 | $122.8M |
| Q4 2019 | $17.2M |
| Q4 2018 | $121.8M |
| Q4 2014 | $101.7M |
| Q4 2013 | $102.9M |
CURI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
CURI has more cash than debt.
NBIS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 0.7x | Very low |
| Q4 2022 | -0.7x | Net Cash |
NBIS's net debt is less than a year of its operating earnings (EBITDA).
CURI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 14.3 | Oversold |
CURI's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
NBIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 8.3 | Oversold |
NBIS's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
CURI PE vs Communication Services Sector
NBIS PE vs Communication Services Sector
| Metric | NBIS | Sector median | Relative |
|---|---|---|---|
| PE | 390x | 16x | 2,264% above |
| PE % | 62 | 24 | 38 pts above |
NBIS is trading at 390x earnings, a 2264% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
CURI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.78 | 2.9% above |
| 20 week MA | $2.75 | 4% above |
| 50 week MA | $3.07 | 6.8% below |
| 100 week MA | $3.49 | 18% below |
| 200 week MA | $2.31 | 24% above |
CURI has stronger trend alignment. CURI is above 3 of 5 weekly averages versus NBIS above 1 of 4.
NBIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $179.7 | 28% below |
| 20 week MA | $199.9 | 36% below |
| 50 week MA | $163.5 | 21% below |
| 100 week MA | $110.0 | 17% above |
NBIS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 17% above its 100-week average.
CURI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.90 | $13.8 | +39% |
| 2021 | $13.8 | $6.44 | -53% |
| 2022 | $6.44 | $1.17 | -82% |
| 2023 | $1.17 | $0.54 | -54% |
| 2024 | $0.54 | $1.58 | +193% |
| 2025 | $1.58 | $3.83 | +142% |
| 2026 YTD | $3.83 | $2.86 | -25% |
CURI's yearly returns have swung widely, from +193% in 2024 to −82% in 2022. It's down 25% so far in 2026.
NBIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.6 | $27.3 | +40% |
| 2025 | $27.3 | $87.6 | +221% |
| 2026 YTD | $87.6 | $128.6 | +47% |
NBIS has the edge over CURI on returns for 2026, with the stronger performance.